David Sperandio

Title: David Sperandio: Innovator in FLT3 Inhibition

Introduction

David Sperandio is a notable inventor based in San Carlos, CA (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit FLT3 activity. His work is crucial for advancing treatments for various proliferative diseases.

Latest Patents

David Sperandio holds a patent for "Pyrazine compounds as inhibitors of FLT3." This patent discloses heterocyclic compounds that inhibit the activity of FLT3. The patent also describes specific covalent inhibitors of FLT3 and pharmaceutical compositions that include these compounds. Methods for using the FLT3 inhibitors, either alone or in combination with other therapeutic agents, are also detailed for the treatment of hematological malignancies and other conditions dependent on FLT3 activity. He has 1 patent to his name.

Career Highlights

David is currently associated with Biomea Fusion, Inc., where he continues to innovate in the field of drug development. His work focuses on creating effective therapies for diseases that rely on FLT3 activity, showcasing his commitment to improving patient outcomes.

Collaborations

David collaborates with esteemed colleagues, including Xiaodong Wang and Thorsten A Kirschberg. Their combined expertise enhances the research and development efforts at Biomea Fusion, Inc.

Conclusion

David Sperandio is a key figure in the development of FLT3 inhibitors, with a focus on creating effective treatments for serious health conditions. His contributions to the field are invaluable and continue to impact the pharmaceutical landscape positively.